AstraZeneca announced in May 2026 that its drug Ultomiris significantly reduced urine protein levels in patients with IgA ...

AstraZeneca (AZN) stock is in focus as the company plans to seek accelerated approval for Ultomiris in IgA nephropathy after ...

Add Yahoo as a preferred source to see more of our stories on Google. May 11—(StatePoint) IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ...

IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...

Adults with IgA nephropathy treated with ravulizumab show significant proteinuria improvement as early as week 10.

AstraZeneca’s Ultomiris met its primary endpoint in the Phase III I CAN trial for IgA nephropathy, significantly reducing proteinuria at 34 weeks. The result marks the first late-stage success for the ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes. A kidney biopsy remains the gold standard for diagnosing IgA ...

IgA nephropathy (IgAN) is a kidney disorder caused by a buildup of immune complexes and the antibody called immunoglobulin A (IgA) inside the kidneys. This buildup causes inflammation in the kidneys.